Continuous glucose monitoring versus finger‑stick checks in pregnancy with type 2 diabetes
Maternal Continuous Glucose Monitoring Surveillance Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
This trial tests whether wearing a continuous glucose monitor helps pregnant people with type 2 diabetes keep up with blood sugar checks more than traditional finger‑stick testing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | Thomas Jefferson University Academic / other |
| Locations | 2 sites (Sewell, New Jersey and 1 other locations) |
| Trial ID | NCT07184775 on ClinicalTrials.gov |
What this trial studies
This randomized trial assigns pregnant people with pregestational type 2 diabetes to either standard finger‑stick glucose monitoring or to wearing a continuous glucose monitor during pregnancy. The main goal is to compare adherence to glucose monitoring between the two methods, with secondary analyses of maternal glycemic control and neonatal outcomes. Eligible participants are those with singleton pregnancies without fetal anomalies who begin prenatal care before 20 weeks; people with type 1 diabetes, insulin allergy, or inability to wear a CGM are excluded. Medication adjustments follow routine clinical care based on the glucose data collected from the assigned monitoring method.
Who should consider this trial
Good fit: Ideal candidates are pregnant people with singleton pregnancies and pregestational type 2 diabetes who start prenatal care before 20 weeks and can wear a continuous glucose monitor.
Not a fit: People with type 1 diabetes, those allergic to insulin, or those unable or unwilling to wear a CGM are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, CGMs could make it easier to track blood sugar during pregnancy and lead to better glucose control and healthier newborn outcomes.
How similar studies have performed: Previous studies in pregnancy and other diabetes populations have shown CGMs increase monitoring adherence and improve glycemic control, but randomized evidence specifically in pregestational T2DM pregnancies is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * singleton pregnancies * fetuses without anomalies * diagnosis of Type 2 diabetes * initiation of prenatal care at \<20 weeks gestation Exclusion Criteria: * diagnosis of Type 1 diabetes * allergy to insulin * inability to wear a continuous glucose monitor
Where this trial is running
Sewell, New Jersey and 1 other locations
- Jefferson Health New Jersey — Sewell, New Jersey, United States (Recruiting)
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Study coordinator: Brandy Firman
- Email: brandy.firman@jefferson.edu
- Phone: 215-955-8401
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.